Steve Schonfeld’s Viking Therapeutics VKTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.09M Buy
+53,683
New +$1.73M 0.01% 1046
2026
Q1
Sell
-67,647
Closed -$2.38M 2711
2025
Q4
$2.38M Sell
67,647
-176,812
-72% -$6.26M 0.01% 814
2025
Q3
$6.42M Buy
+244,459
New +$7.29M 0.04% 496
2025
Q2
Sell
-228,474
Closed -$5.52M 2575
2025
Q1
$5.52M Buy
+228,474
New +$7.22M 0.03% 495
2024
Q4
Sell
-51,109
Closed -$3.24M 2418
2024
Q3
$3.24M Buy
51,109
+22,467
+78% +$1.32M 0.02% 694
2024
Q2
$1.52M Sell
28,642
-5,007
-15% -$328K 0.01% 1027
2024
Q1
$2.76M Buy
+33,649
New +$1.5M 0.02% 878
2023
Q4
Sell
-53,900
Closed -$597K 2251
2023
Q3
$597K Buy
53,900
+7,947
+17% +$114K ﹤0.01% 1161
2023
Q2
$745K Sell
45,953
-284,402
-86% -$5.96M 0.01% 1080
2023
Q1
$5.5M Buy
330,355
+195,211
+144% +$2.02M 0.05% 417
2022
Q4
$1.27M Buy
135,144
+56,924
+73% +$254K 0.01% 1031
2022
Q3
$213K Sell
78,220
-9,500
-11% -$31.1K ﹤0.01% 2296
2022
Q2
$254K Buy
+87,720
New +$217K ﹤0.01% 1758
2019
Q3
Sell
-475,400
Closed -$3.95M 1256
2019
Q2
$3.95M Sell
475,400
-178,900
-27% -$1.53M 0.14% 179
2019
Q1
$6.5M Buy
+654,300
New +$5.48M 0.23% 120

Other funds holding VKTX

Steve Schonfeld's VKTX Position: Q2 2026 in Review

Steve Schonfeld opened a new position in Viking Therapeutics (VKTX) in Q2 2026: 53,683 shares worth $2.09M. The stake represents 0.01% of the portfolio and ranks #1046 among its holdings. This is a return to the name: Steve Schonfeld previously reported a position in VKTX as recently as Q4 2025.

Steve Schonfeld first reported a position in VKTX in Q1 2019 and has held it in 15 quarters since. The position peaked at $6.5M in Q1 2019. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Steve Schonfeld held 53,683 shares of Viking Therapeutics worth $2.09M as of Q2 2026.
  • Viking Therapeutics was a new Steve Schonfeld position in Q2 2026.
  • Viking Therapeutics made up 0.01% of Steve Schonfeld's portfolio in Q2 2026, its #1046 holding.
  • Steve Schonfeld first reported a position in Viking Therapeutics in Q1 2019 and has held it in 15 quarters since.
  • Steve Schonfeld's Viking Therapeutics position peaked at $6.5M in Q1 2019.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.